Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA8212
Study Title: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non Muscle Invasive Bladder Cancer (BRIDGE)
CTO #: 103852
NCT Number: NCT05538663
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: To determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical BCG vs GEMDOCE. To compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE.